Table 2.
OS multivariate cox hazards analysis
| Variables | HR | 95%CI | P | Wald | B | SE |
|---|---|---|---|---|---|---|
| CEA | ||||||
| ≤ 9.8 | Ref | |||||
| > 9.8 | 0.704 | 0.487–1.018 | 0.062 | 3.486 | −0.351 | 0.188 |
| WBC | ||||||
| ≥ 3.5 | Ref | |||||
| < 3.5 | 1.326 | 0.706–2.493 | 0.38 | 0.769 | 0.282 | 0.322 |
| NLR | ||||||
| ≤ 5.06 | Ref | |||||
| > 5.06 | 1.538 | 1.045–2.263 | 0.029 | 4.772 | 0.430 | 0.197 |
| Types of ICIs | ||||||
| Camrelizumab | Ref | |||||
| Pembrolizumab | 1.756 | 0.789–3.909 | 0.168 | 1.905 | 0.563 | 0.408 |
| Sintilimab | 0.654 | 0.400–1.067 | 0.089 | 2.887 | −0.425 | 0.250 |
| Tislelizumab | 1.236 | 0.785–1.947 | 0.360 | 0.837 | 0.212 | 0.232 |
| Other | 1.344 | 0.701–2.578 | 0.373 | 0.792 | 0.296 | 0.332 |
| Smoking history | ||||||
| No | Ref | |||||
| Yes | 1.377 | 0.965–1.964 | 0.078 | 3.115 | 0.320 | 0.181 |
| Surgery | ||||||
| No | Ref | |||||
| Yes | 0.493 | 0.312–0.780 | 0.003 | 9.131 | −0.707 | 0.234 |
| Radiotherapy(baseline) | ||||||
| No | Ref | |||||
| Yes | 1.388 | 0.855–2.254 | 0.185 | 1.755 | 0.328 | 0.247 |
| Staging | ||||||
| II-III | Ref | |||||
| IV | 1.781 | 1.124–2.822 | 0.014 | 6.030 | 0.577 | 0.235 |
| Treatment Plan | ||||||
| ICIs + chemotherapy | Ref | |||||
| ICIs + chemotherapy + AATs | 1.643 | 0.976–2.767 | 0.062 | 3.486 | 0.497 | 0.266 |
| ICIs + AATs | 0.746 | 0.439–1.269 | 0.280 | 1.166 | −0.292 | 0.271 |
| ICIs | 0.477 | 0.215–1.060 | 0.069 | 3.300 | −0.740 | 0.407 |
| Lines | ||||||
| 1 | Ref | |||||
| 2 | 1.234 | 0.751–2.028 | 0.407 | 0.687 | 0.210 | 0.254 |
| > 2 | 2.634 | 1.531–4.533 | < 0.001 | 12.229 | 0.968 | 0.277 |
| ECOG PS | ||||||
| 0 ~ 1 | Ref | |||||
| > 2 | 1.404 | 0.869–2.271 | 0.166 | 1.920 | 0.340 | 0.245 |
| Efficacy assessment | ||||||
| PD | Ref | |||||
| SD | 0.568 | 0.387–0.833 | 0.004 | 8.381 | −0.566 | 0.195 |
| PR | 0.213 | 0.104–0.435 | < 0.001 | 18.008 | −1.547 | 0.365 |
| AE grade | ||||||
| 0 | Ref | |||||
| 1 ~ 2 | 0.681 | 0.468–0.990 | 0.044 | 4.042 | −0.384 | 0.191 |
| 3 + | 1.204 | 0.673–2.153 | 0.532 | 0.391 | 0.186 | 0.297 |
| Liver metastases | ||||||
| No | Ref | |||||
| Yes | 2.514 | 1.217–5.195 | 0.013 | 6.199 | 0.922 | 0.370 |
| Bone metastases | ||||||
| No | Ref | |||||
| Yes | 1.509 | 0.913–2.495 | 0.109 | 2.573 | 0.411 | 0.257 |
| Other metastases | ||||||
| No | Ref | |||||
| Yes | 0.673 | 0.403–1.122 | 0.129 | 2.309 | −0.396 | 0.261 |
WBC White blood cell count, CEA Carcinoembryonic antigen, NEU_LYM Neutrophil/lymphocyte ratio, AATs Anti-angiogenesis therapies, ECOG PS Eastern Cooperative Oncology Group Performance Status, AE Adverse event, PD Progressive disease, PR Partial response, SD Stable disease